Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders

Definitions

• the present invention relates to pharmaceutical compositions containing N-palmitoylethanolamide (palmidrol) for use m the veterinary field, particularly for the treatment of the eosinophilic skin condition in felines which is normally known as Eosinophilic Granuloma Complex, and of tendonous keloids m horses.
• N-palmitoylethanolamide palmidrol
• the eosinophilic condition in felines (Moriello K et al, 1997, Handbook of Small Animal Dermatology, pp. 205- 208, Pergamon Press) has clinical signs such as erythema, pru ⁇ tis and alopecia, and skin symptoms which are recognizable m the form of eosinophilic plaque (EP) , eosinophilic granuloma (EG) , and miliary or papulo-scabby dermatitis, which can appear m the animal individually or simultaneously or at different times.
• EP eosinophilic plaque
• EG eosinophilic granuloma
• miliary or papulo-scabby dermatitis which can appear m the animal individually or simultaneously or at different times.
• EP is a circumscribed area of erosion and exudation associated with clinical signs such as erythema, pru ⁇ tis and auto- induced alopecia. Although they may appear anywhere on the skm surface, the lesions are located preferentially m the inguinal or perianal regions or m the medial region of the upper rear leg.
• the characteristic hystopathology of EP shows considerable cell infiltration m the pe ⁇ vascular spaces, associated with epidermal hyperplasia, spongiosis and ulceration.
• EG appears as an erythematous , alopecic and raised area generally located on the caudal face of the rear paws on the extremities (the claw bed and the pads) , in the oral cavity, or on the chin.
• the characteristic hystopathology of EG appears as a diffuse granulomatous dermatitis associated with areas of collagenolysis .
• Miliary dermatitis is similar to EP but less extensive and with the formation of scabs.
• eosinophilic granuloma with lesions is a highly recurrent condition.
• animals suffering from eosinophilic granuloma, m the form either of EP or of EG are- subject throughout their lives, to intermittent or continuous treatments with antihistammes and corticosteroids the side effects of which, particularly m treatment of long duration, are known and documented.
• Tendonous keloids represent one of the most common chronic manifestations of tendinitis which arise in horses - and in particular in competition horses - as a result of acute inflammations of the tendons, as well as partial or complete traumatic lesions and also lesions associated with haemorrhage and oedema.
• Tendonous keloids appear as soft, easily palpable masses of variable sizes and are constituted by fibrous tissue with thickenings and adhesions in the peritendonous area. Horses with chronic tendon symptoms of this type notice pain with clear lameness which greatly comprise their competitive performance.
• N- palmitoylethanolamide (common international name : palmidrol) is effective in the treatment of eosinophilic granuloma m cats, for both EP and EG lesions, and of tendonous keloids m horses. In the latter case m particular, a complete recovery of the animal with the possibility of a return to the competition circuit has been confirmed.
• the subject of the present invention is therefore the use of n-palmitoylethanolamide, preferably m micronized and/or co-micronized form, for the preparation of pharmaceutical compositions for veterinary use, particularly for the treatment of eosinophilic granuloma in cats, for both EP and EG lesions, and of tendonous keloids m horses.
• a further subject of the present invention is pharmaceutical compositions containing N- palmitoylethanolamide m micronized and/or co-micronized form.
• the treatment of cats with N-palmitoylethanolamide provides for the administration of the drug m quantities of from 1 to 50 mg/kg/die for a period of between 15 and 60 days.
• a preferred treatment scheme provides for a daily administration of 10 mg/kg of body weight for 30 consecutive days.
• the treatment of horses with N-palmitoylethanolamide provides for the administration of the drug in quantities of from 0.5 to 5 g/die, preferably 2 g/die for a period of between 20 and 150 consecutive days, preferably between 30 and 120 days.
• the improvements in the clinical signs and in the associated lesions were evaluated on the 15th and 30th days of treatment .
• the treatment consisted of a preparation in accordance with Example 3 of the pharmaceutical preparations given below, containing 120 mg of micronized N-palmitoylethanolamide.
• the active ingredient was administered in a proportion of 10 mg/kg/die for 30 days.
• Example 1 of the pharmaceutical compositions given below Treatment for 30 days with the preparation of Example 1 of the pharmaceutical compositions given below, involving administration of 2 g/die of micronized N- palmitoylethanolamide, brought about a regression of the keloid by between 90 and 95%.
• the animal was able to recommence competitive activity.
• a 5 -year-old male bay racehorse had signs of recurrent, chronic tendon inflammation on the right-hand front profound flexor. 2 years previously, the subject had undergone a tendonectomy for lesion to the sheath, from which it had never fully recovered. After treatment for 30 days with the preparation of Example 1 of the pharmaceutical preparations given below, involving the administration of 2 g/die of micronized N- palmitoylethanolamide , the tendon was clearly reduced. After a further 30 days with the same treatment regime, the subject was completely cured with considerable benefit to its competitive performance.
• N- palmitoylethanolamide can advantageously be used in the treatment of eosinophilic granuloma in cats, for both EP and EG lesions, and of tendonous keloids m horses, both when these conditions are acute and when they are chronic .
• N-palmitoylethanolamide m micronized and/or co-micronized form is particularly advantageous m bringing about the positive outcome of the treatment
• N-palmitoylethanolamide preferably m micronized and/or co-micronized form
• for the treatment of eosinophilic granuloma m cats, for lesions m both EP and EG forms, and of tendonous keloids m horses, may be extended to all animals, particularly felines and equmes, which have conditions of the same type.
• PEA is a known compound and can be prepared in accordance with the synthesis method described m EP 0 550 008 which is incorporated herein by reference.
• PEA micronization of PEA and its co-micronization with excipients were performed with compressed-air turbine micronizmg apparatus. This apparatus is known and is not therefore described m greater detail .
• Example 1 oral powder for horses
• Example 2 oral granules for horses 100 g contained:
• Example 3 tablets for cats
• Each tablet divisible from 350 g, contained: micronized N-palmitoylethanolamide 120 mg maize starch 30 mg lactose 115 mg carboxymethyl cellulose 15 mg microcrystalline cellulose 60 mg magnesium stearate 10 mg
• Example 4 - oily gel for cats 100 g contained:
• N-palmitoylethanolamide 1.5 g soya lecithin 82.5 g geleol 12.0 g
• Vitamin E acetate 0.5 g
• Example 5 Gel for use on oral mucosae in cats 100 g contained: micronized N-palmitoylethanolamide 300 mg hyaluronic acid, sodium salt
• composition for administration to cats contains from 20 mg to 4 g of PEA per 100 g of composition.
• a composition for administration to horses contains from 15 g to 40 g of PEA per 100 g of composition.
• compositions containing a pharmacologically effective dose of N- palmitoylethanolamide together with pharmacologically acceptable excipients may be provided.
• These compositions may be in the form of capsules, tablets, powders and pellets, and also in gastroresistant formulations for oral administration and may also be produced with the use of preliminary microencapsulation, liposomization or micellization techniques.
• formulations in suppositories, micro-enemas, creams, ointments, sprays, gels, foams, dressings of various thicknesses and patches may be used. All possible pharmaceutical forms indicated for the various administration routes may also be formulated with excipients or by technological processes suitable for producing fast-release or slow-release medicaments .

Priority Applications (7)

Applications Claiming Priority (1)

Publications (1)

Family

ID=11333115

Family Applications (1)

Country Status (7)

Cited By (4)

Families Citing this family (12)

Citations (4)

• 1999
  • 1999-08-06 US US10/030,060 patent/US6548550B1/en not_active Expired - Lifetime
  • 1999-08-06 WO PCT/IT1999/000259 patent/WO2001010434A1/en active IP Right Grant
  • 1999-08-06 EP EP99939603A patent/EP1207870B1/en not_active Expired - Lifetime
  • 1999-08-06 DK DK99939603T patent/DK1207870T3/da active
  • 1999-08-06 AT AT99939603T patent/ATE290858T1/de active
  • 1999-08-06 DE DE69924304T patent/DE69924304T2/de not_active Expired - Lifetime
  • 1999-08-06 ES ES99939603T patent/ES2239453T3/es not_active Expired - Lifetime

Patent Citations (4)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events